Segmental Reporting

12 Months Ended

Dec. 31, 2013

Segment Reporting [Abstract]

Segment Reporting Disclosure

24.       Segmental reporting

Historically the Company had three business units and three reportable segments: Specialty Pharmaceuticals (“SP”), Human Genetic Therapies (“HGT”) and RM.

On May 2, 2013 the Company announced that there would be a reorganization of the Company's business to integrate the operation of these business units into a simplified One Shire organization in order to drive future growth and innovation. Consequently the SP, HGT and RM segmentsno longer exist.

Shire now comprises a single operating and reportable segment, consistent with the One Shire approach that underpins the business simplification. This segment is engaged in the research, development, licensing, manufacturing, marketing, distribution and sale of innovative specialist medicines to meet significant unmet patient needs.

This segment is supported by several key functions: a Pipeline group, consisting of R&D and Business Development, will prioritize its activities towards late stage development programs across a variety of therapeutic areas, while focusing its pre-clinical development activities primarily in rare diseases; a Technical Operations group will be responsible for the Company's global supply chain; and an In-line marketed products group will focus on commercialized products. The In-Line marketed products group currently consists of four commercial units focused exclusively on commercial delivery to drive optimum performance of currently marketed products. The business is also supported by a simplified, centralized corporate function group. None of these functional groups meets all of the criteria to be an operating segment.

The reorganization to a single operating and reportable segment is consistent with the financial information regularly reviewed by the Executive Committee (which is Shire's chief operating decision maker) for the purposes of evaluating performance, allocating resources, and planning and forecasting future periods.

Geographic information

Revenues (based on the geographic location from which the sale originated):

	2013	2012	2011
Year to December 31,	$’M	$’M	$’M
	___________	___________	___________
Ireland	22.5	20.6	21.1
United Kingdom	206.7	207.0	219.9
North America	3,386.2	3,006.1	2,761.8
Rest of World	1,318.9	1,293.7	1,155.3
	____________	____________	____________
Total revenues	4,934.3	4,527.4	4,158.1
	____________	____________	____________

Long-lived assets comprise all non-current assets, (excluding goodwill and other intangible assets, deferred contingent consideration assets, deferred tax assets, investments and financial instruments) based on the geographic location within which the economic benefits arise:

	2013	2012
Year to December 31,	$’M	$’M
	___________	___________
Ireland	5.8	5.2
United Kingdom	70.3	72.2
North America	802.9	861.0
Rest of World	13.8	18.8
	____________	____________
Total	892.8	957.2
	____________	____________

Material customers

In the periods set out below, certain customers, accounted for greater than 10% of the Company's product revenues:

	2013	2013	2012	2012	2011	2011
Year to December 31,	$’M	% product revenue	$’M	% product revenue	$’M	% product revenue
	___________	___________	___________	___________	___________	___________
McKesson Corp.	902.9	19	835.9	20	742.9	19
Cardinal Health Inc.	853.7	18	1,035.7	24	923.9	24
AmerisourceBergen Corp	721.0	15	307.4	7	276.4	7
	____________	___________	____________	___________	____________	___________
Amounts outstanding as at December 31, in respect of these material customers were as follows:
					2013	2012
December 31,					$’M	$’M
					___________	___________
McKesson Corp.					161.3	127.4
Cardinal Health Inc.					149.5	166.1
AmerisourceBergen Corp					164.6	47.4
					____________	___________

In the periods set out below, revenues by major product were as follows:

	2013	2012	2011
	$’M	$’M	$’M
	___________	___________	___________
VYVANSE	1,227.8	1,029.8	805.0
ELAPRASE	545.6	497.6	464.9
LIALDA/MEZAVANT	528.9	399.9	372.1
REPLAGAL	467.9	497.5	475.2
ADDERALL XR	375.4	429.0	532.8
VPRIV	342.7	306.6	256.2
INTUNIV	334.9	287.8	223.0
PENTASA	280.6	265.8	251.4
FIRAZYR	234.8	116.3	33.0
FOSRENOL	183.4	172.0	166.9
XAGRID	99.4	97.2	90.6
Other product sales	136.1	153.4	173.8
	____________	____________	____________
Total product sales	4,757.5	4,252.9	3,844.9
	____________	____________	____________